PODCAST · health
GHAPPcast
by Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
Episodes
-
Linerixibat Medication Review
Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in primary biliary cholangitis (PBC). This medication review podcast explores how blocking bile acid...
-
Podcast: Managing Fatigue and Pruritus in Your Patients With PBC
How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact of PBC-related pruritus and fatigue on sleep, daily activities, and quality of life. The...
-
Podcast: How to Screen and Diagnose Cholestatic Liver Diseases
In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liver disease. The conversation reviews how to recognize a cholestatic liver test pattern, evaluate...
-
GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy
Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing and managing overt hepatic encephalopathy (OHE) in patients with chronic liver disease and...
-
FAQ: Counseling Patients on Overt Hepatic Encephalopathy
Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hepatic encephalopathy (OHE). This educational overview explains how cirrhosis and portal...
-
FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy
Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephalopathy (OHE) in patients with severe liver disease or cirrhosis. This educational overview...
-
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussion with Amanda Wilhite, PA-C, of Houston Methodist Gastroenterology Associates. The episode…
more -
Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC
Thank you to AbbVie for their support of this Medication Review Video Module. In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the INSPIRE and COMMAND clinical trials evaluating risankizumab for the treatment of moderately to...
-
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC, from the University of California San Diego, provide a comprehensive overview of the SEQUENCE...
-
FAQ: QUASAR Long Term Extension Interim Analysis
Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data evaluating the efficacy and safety of guselkumab in adults with moderate to severe ulcerative...
-
Medication Review: Guselkumab IV vs SC Formulation
Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory Bowel Disease Center, discusses an important question in Crohn’s disease treatment. This…
more -
FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease
Thank you to Salix for the support on this FAQ Video Module. This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepatic Encephalopathy (OHE) in patients with chronic liver disease and cirrhosis. A central focus is...
-
FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease
Thank you to Johnson & Johnson for the support on this FAQ Video Module. This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in patients with moderately to severely active Crohn’s disease. In this expert-led discussion, she...
-
Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy
Thank you to Celltrion for the support on this Medication Review Video Module. This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammatory bowel disease (IBD), with a focus on biologic optimization and patient-centered treatment...
-
Medication Review: Stable PK Supporting Continuous Inflammatory Control
Thank you to Celltrion for the support on this Medication Review Video Module. This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in inflammatory bowel disease (IBD), with a focus on subcutaneous infliximab therapy for Crohn’s...
-
Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab
Thank you to Johnson & Johnson for the support on this Journal Club Review Module. In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews the ASTRO trial published in The Lancet, which evaluated subcutaneous guselkumab for the…
more -
Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD
Thank you to AbbVie for the support on this Journal Club Review Module. This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely active Ulcerative Colitis and Crohn’s Disease, based on a post hoc analysis of phase 2b/3 clinical...
-
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specialists Robin Soto and Alison Moe break down how to set realistic expectations, define meaningful...
-
Podcast: Best Practices For Patient Identification
Stay up to date on MASH and MASLD with expert insights from nurse practitioners Sarah Dawkins of Duke University Medical Center and Edith Johannes of UCLA Health. This episode focuses on best practices for identifying at-risk patients, including those with steatosis on imaging, cardiometabolic…
more -
Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
In this episode of RhAPPcast, host Amanda Mixon, PA-C, is joined by Christina Hanson, NP, to explore the growing intersection between rheumatology and gastroenterology, focusing on shared immune pathways and the evolving role of subcutaneous biologic therapies in immune-mediated inflammatory...
-
FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
Thank you to Johnson & Johnson for the support on this FAQ Video Module. In this FAQ video module, Tedra Gray, a gastroenterology nurse practitioner at Sinai Chicago, breaks down the key differences between treat-through and randomized withdrawal clinical trial designs in inflammatory bowel…
more -
Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data
Thank you to Johnson & Johnson for the support on this Medication Review Video Module. In this medication review video module, Kimberly Orleck, PA-C, reviews the long-term efficacy and safety of guselkumab in the treatment of Crohn’s disease, highlighting results from the Phase 3 GALAXI-2,...
-
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
In this podcast, host Amanda Mixon, PA-C, leads a 2026 Fireside Chat exploring the intersection of rheumatology and gastroenterology. Joined by Kim Orleck, PA-C (GI APP), and Wendy Simmons, PA-C (Rheumatology APP), the panel discusses the shared inflammatory pathways linking Crohn’s disease,...
-
Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results
Thank you to AbbVie for the support on this Journal Club Review Video Module. In this journal club review, Kimberly Orleck, PA-C, discusses the long-term efficacy and safety of risankizumab, an IL-23 p19 inhibitor, in moderate to severely active Crohn’s disease, highlighting results from the...
-
Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know
Thank you to AbbVie for the support on this podcast episode. In this GHAPP podcast episode, Brooke Hodnik, PA, and Jamie Brogan, APRN, discuss the October 10, 2025 FDA label update for upadacitinib in adults with moderate to severe ulcerative colitis and Crohn’s disease. They break down what the...
-
FAQ: Biomarkers: The Non-Invasive Future of HCC Detection
Thank you to Fujifilm for their support on this FAQ Video Module. In this FAQ video module, Patrick Horne, NP, President of GHAPP and nurse practitioner at the University of Florida, provides a clear, practical overview of FDA-cleared biomarkers used in the detection and risk assessment of...
-
FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications
Thank you to AbbVie for their support on this FAQ Video Module. In this FAQ video module, Brooke Hodnick, PA-C, breaks down key updates to the expanded upadacitinib label for adults with moderate to severe ulcerative colitis and Crohn’s disease, effective October 10, 2025. The discussion focuses…
more -
FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?
Thank you to AbbVie for their support on this FAQ Video Module. In this FAQ video module, Jamie Brogan, APRN from the IBD Center at Northwestern Medicine, breaks down the October 2025 FDA label expansion for upadacitinib in adult patients with moderate to severely active ulcerative colitis and...
-
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Allysa Saggese, NP, reviews how clinicians can balance systemic and liver-directed therapies in the treatment of metabolic dysfunction–associated steatohepatitis (MASH) and shares insights on the evolving role of...
-
FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?
Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Alison Moe, PA-C, discusses how alcohol consumption impacts the evaluation and progression of metabolic dysfunction–associated steatohepatitis (MASH) and why accurate assessment is critical in clinical practice....
-
Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment
Thank you to Madrigal for their support of this Medication Review Video Module. In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic...
-
APP Roundtable: Approach To Starting Treatments in Patients With CHB
In this expert-led podcast discussion on hepatitis B management, Elizabeth Goacher, PA-C, from Duke University Medical Center and Allison Moser, NP, from RUSH University Medical Center break down what’s new in chronic hepatitis B care and how evolving guidelines are shaping real-world clinical...
-
APP Roundtable: Navigating Difficult Conversations in CHB
This in-depth conversation explores how advanced practice providers navigate some of the most challenging discussions in the care of patients living with chronic hepatitis B. Drawing from years of real-world hepatology and transplant experience, Jennifer Geremia, PA-C, and Andrea Keller, PA,...
-
APP Roundtable: Addressing Co-Morbidities in CHB
In this expert-led podcast discussion, Patrick Horne and HoChong Gilles explore the complex management of comorbidities in patients with chronic viral hepatitis, with a focus on hepatitis B, hepatitis C, and HIV co-infection. The conversation highlights practical strategies for treatment...
-
FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?
Thank you to Madrigal for your support on this FAQ Video Module. In this short FAQ video module, Patrick Horne, President of GHAPP and a nurse practitioner at the University of Florida, discusses the critical role of noninvasive tests (NITs) in risk stratification and patient selection for…
more -
Journal Club: Review of Focused Recommendations for the Management of MASLD
Thank you to Madrigal for your support on this Journal Club Review video module. This journal club review explores the 2025 focused recommendations for the management of metabolic dysfunction–associated steatohepatitis (MASH) developed by advanced practice providers (APPs) across the United…
more -
Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations
Thank you to Madrigal for your support of this Medication Review Video Module. Discover how Resmetirom is reshaping the treatment landscape for metabolic dysfunction–associated steatohepatitis (MASH) in this expert-led medication review with HoChong Gilles, DNP. This short medication review…
more -
FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients?
Thank you to Madrigal for your support on this FAQ Video Module. In this episode, Christina Hanson, NP, breaks down the key functional and prognostic differences between fibrosis stage F3 and F4, explaining how liver architecture, portal hypertension, and risk of decompensation shape patient...
-
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
In this final episode of our RhAPP, MAPP, GHAPP, and SDPA crosscast series, expert APPs from dermatology, gastroenterology, rheumatology, and obesity medicine break down the most important conversation of all—how to talk to patients about obesity and immune-mediated inflammatory diseases (IMIDs)....
-
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
In this cross-specialty episode of our RhAPP, GHAPP, MAPP and SDPA collaborative series, leading APPs from dermatology, gastroenterology, rheumatology, and metabolic medicine break down real-world strategies to improve outcomes for patients living with both obesity and immune-mediated…
more -
GHAPPcast: Women of Childbearing Age With IBD
Thank you to AbbVie for your support on this podcast episode. Navigating pregnancy with inflammatory bowel disease (IBD) can bring unique questions, concerns, and misconceptions—especially for women of childbearing age. In this expert-led episode, Janette Villalon, PA and Angelina Collins, MSN,...
-
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
In this episode of our crosscast series shared across RhAPPcast, GHAPPcast, and Dermcast, we explore the hidden costs of obesity in immune-mediated inflammatory diseases (IMIDs) and how excess adiposity drives poorer outcomes, reduced treatment response, and increased healthcare burden. Hosted by...
-
FAQ: How Do You Explain Remission To A Patient?
Thank you to AbbVie for your support on this FAQ Video Module. In this GHAPP FAQ Video Module, Christie Morrison, from Oshi Health and Texas Digestive Disease Consultants, explains how to discuss clinical remission with patients living with inflammatory bowel disease (IBD), including both Crohn’s...
-
GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient
Thank you to AbbVie for your support on this podcast. In this episode of the GHAPP Podcast, Alison Krustapentus, NP-C and Christie Morrison, NP, join for an open discussion on mental and sexual health in inflammatory bowel disease (IBD). Together they explore the often-overlooked psychological…
more -
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
Welcome to the first episode in our special cross-platform podcast collaboration on IMIDs and Obesity, shared across RhAPPcast, GHAPPcast, and Dermcast—the official podcasts of RhAPP, GHAPP, and SDPA. Hosted by Amanda Mixon, PA-C, President of RhAPP, this conversation titled “Obesity and IMIDs:...
-
APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?
Thank you to Ardelyx for your support on this APP Insight video module. In this video, Amy Ladewski, PA-C, a physician assistant at Northwestern Memorial Hospital in Chicago, shares expert insights on how to develop a personalized treatment plan for irritable bowel syndrome with constipation...
-
GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
Thank you to Ardelyx for your support on this podcast episode. In this podcast, Gabriella McCarty, NP, and Kimberly Orleck, PA-C, dive into the complexities of irritable bowel syndrome with constipation (IBS-C) and the wide range of therapies available to help patients. They discuss the…
more -
GHAPPcast: Smarter Surveillance: The Rise of Algorithms like GALAD and Their Path to Practice
Thank you to Fujifilm for your support on this podcast episode. In this episode of GHAPPcast, the official podcast of Gastroenterology and Hepatology Advanced Practice Providers, host Samantha Ramirez, NP-C is joined by Tracy Licari, PA-C to explore the rise of biomarker-based algorithms like…
more -
FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?
Thank you to AbbVie for your support of this FAQ Video Module. In this educational discussion, Mikhail Alper, PA-C, from Fresno, California, highlights the critical role of biomarkers like fecal calprotectin and C-reactive protein (CRP) in managing inflammatory bowel disease (IBD), including...
-
FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?
Thank you to AbbVie for your support of this FAQ Video Module. In this educational video, Alison Krustapentus, NP-C from Beth Israel Deaconess Medical Center in Boston discusses how to approach persistent inflammation in patients with inflammatory bowel disease (IBD). She outlines a step-by-step...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).
Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
HOSTED BY
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Loading similar podcasts...
Frequently Asked Questions
How many episodes does GHAPPcast have?
GHAPPcast currently has 164 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is GHAPPcast about?
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through...
How often does GHAPPcast release new episodes?
GHAPPcast publishes regularly with 164 episodes available. Check the episode list for the typical release schedule.
Where can I listen to GHAPPcast?
You can listen to GHAPPcast on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts GHAPPcast?
GHAPPcast is created and hosted by Gastroenterology & Hepatology Advanced Practice Providers (GHAPP).
URL copied to clipboard!